Jorveza

Budesonide, the active ingredient in Jorveza, is a corticosteroid presented as an oral suspension for oral use. It is indicated for the treatment of mild to moderate Crohn's disease affecting the ileum and/or right colon in adult patients. The formulation delivers high local anti‑inflammatory activity while limiting systemic exposure, making it suitable for targeted gastrointestinal therapy.

GNH USA supplies Jorveza as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU regulations and provides reliable global distribution.

Jorveza (budesonide) acts within the gastrointestinal inflammatory disease pathway, specifically targeting Crohn's disease.

Crohn's disease (ileum and right colon): reduces intestinal inflammation and helps achieve clinical remission in mild to moderate cases. Crohn's disease (overall mild to moderate): improves symptoms such as abdominal pain, diarrhea, and weight loss, supporting patient quality of life. Localized disease in the ileum/right colon: provides targeted anti‑inflammatory effect, reducing the need for systemic corticosteroids.

Common Side Effects: - Headache - Nausea - Abdominal pain - Upper respiratory tract infection

Serious or Rare Side Effects: - Adrenal suppression - Severe infection - Hypersensitivity reactions - Cushing's syndrome

Before prescribing Jorveza, clinicians should consider several safety measures. - Assess disease severity before initiating: confirm mild to moderate Crohn's disease limited to ileum/right colon. - Monitor adrenal function during prolonged therapy: check cortisol levels as indicated. - Avoid use in active untreated infections: treat infection prior to starting therapy. - Use caution in diabetic patients: monitor blood glucose as corticosteroids may affect control. - Pregnancy and lactation: discuss potential risks with healthcare provider. - Store at ambient temperature: keep below 25 °C, protect from moisture, retain in original container.

Jorveza may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide exposure. - Concurrent systemic corticosteroids: additive immunosuppression and adrenal suppression risk. - Antifungal agents (e.g., posaconazole): may raise budesonide levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce budesonide efficacy. - Oral contraceptives: possible reduced hormonal effectiveness. - Live vaccines: may have diminished immune response.